Key Events This Week
09 Feb: Stock rallies 5.20% on strong volume, outperforming Sensex
10 Feb: Valuation shifts to fair amid mixed market performance
11 Feb: Q3 FY26 results reveal strong profit surge
12-13 Feb: Profit-taking leads to declines despite broader market weakness
09 February 2026: Strong Opening Rally Outpaces Sensex
Par Drugs & Chemicals Ltd began the week with a robust gain of 5.20%, closing at Rs.96.49 on 9 February 2026. This surge was accompanied by a significant volume of 14,471 shares, signalling strong investor interest. The Sensex also advanced by 1.04% to 37,113.23, but the stock’s outperformance was clear, setting a positive tone for the week.
10 February 2026: Valuation Recalibrated to Fair Amid Mixed Market Signals
On 10 February, the stock edged up marginally by 0.19% to Rs.96.67, with volume tapering to 8,070 shares. This day marked a key development as the company’s valuation shifted from attractive to fair. The price-to-earnings ratio stood at 12.02, and the price-to-book value ratio was 1.18, reflecting a more balanced market perception. Compared to sector peers with significantly higher multiples, Par Drugs & Chemicals’ valuation appeared reasonable, appealing to value-oriented investors despite the stock trading well below its 52-week high of Rs.190.24.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
11 February 2026: Q3 FY26 Earnings Reveal Strong Profit Surge
The stock experienced its highest close of the week on 11 February, surging 5.17% to Rs.101.67 on heavy volume of 50,896 shares. This rally coincided with the release of the company’s Q3 FY26 results, which showcased a strong profit surge. While the quarterly earnings performance was encouraging, it masked a more troubling long-term trajectory, with the stock’s one-year and three-year returns deeply negative. The strong short-term earnings momentum provided a catalyst for the price spike, though investors remained cautious about the sustainability of this growth.
12-13 February 2026: Profit-Taking Amid Broader Market Weakness
Following the earnings-driven rally, Par Drugs & Chemicals Ltd saw a reversal in the last two trading sessions. On 12 February, the stock declined 1.79% to Rs.99.85 on lower volume of 5,938 shares, while the Sensex fell 0.56%. The downtrend intensified on 13 February, with the stock dropping 2.95% to close at Rs.96.90, as the Sensex declined 1.40%. These sessions reflected profit-taking and a cautious market mood, with the stock retreating from its weekly high but still maintaining a solid weekly gain.
Why settle for Par Drugs & Chemicals Ltd? SwitchER evaluates this micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Weekly Price Performance: Par Drugs & Chemicals Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-09 | Rs.96.49 | +5.20% | 37,113.23 | +1.04% |
| 2026-02-10 | Rs.96.67 | +0.19% | 37,207.34 | +0.25% |
| 2026-02-11 | Rs.101.67 | +5.17% | 37,256.72 | +0.13% |
| 2026-02-12 | Rs.99.85 | -1.79% | 37,049.40 | -0.56% |
| 2026-02-13 | Rs.96.90 | -2.95% | 36,532.48 | -1.40% |
Key Takeaways
Positive Signals: Par Drugs & Chemicals Ltd outperformed the Sensex by a wide margin this week, gaining 5.65% versus the benchmark’s 0.54% decline. The valuation shift to a fair rating reflects a more balanced market view, supported by solid profitability metrics such as a 22.22% ROCE. The strong Q3 profit surge provided a clear catalyst for the midweek rally, demonstrating the company’s capacity to deliver earnings growth in the short term.
Cautionary Notes: Despite the weekly gains, the stock remains well below its 52-week high of Rs.190.24, highlighting a challenging longer-term performance. The one-year and three-year returns remain deeply negative, signalling persistent structural issues. The recent profit-taking and volume decline in the last two sessions suggest investor caution amid broader market weakness. The PEG ratio at zero indicates limited growth visibility, which may restrain enthusiasm among growth-focused investors.
Conclusion
Par Drugs & Chemicals Ltd’s week was characterised by a strong start and midweek rally driven by valuation recalibration and robust quarterly earnings. However, the subsequent profit-taking and broader market declines tempered gains, resulting in a modest weekly advance of 5.65%. The stock’s fair valuation and solid capital efficiency metrics provide a foundation for stability, but the long-term negative returns and limited growth visibility warrant a cautious outlook. Investors should monitor upcoming earnings and sector developments closely to assess whether the recent momentum can be sustained.
Unlock special upgrade rates for a limited period. Start Saving Now →
